Advertisement

SGLT2 inhibition

Open Access
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
Adeera Levin, Vlado Perkovic, David C. Wheeler, Stefan Hantel, Jyothis T. George, Maximilian von Eynatten, Audrey Koitka-Weber, Christoph Wanner and on behalf of the EMPA-REG OUTCOME Investigators

CJASN October 2020, 15 (10) 1433-1444; DOI: https://doi.org/10.2215/CJN.14901219

Add to Selected Citations